Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma

Hirata,Tomomi; Zheng,Qingfeng; Chen,Zhao; Kinoshita,Hiroyasu; Okamoto,Junichi; Kratz,Johannes; Li,Hui; Lui,Natalie; Do,Hanh; Cheng,Tiffany; Tseng,Hsin-Hui   Katty; Koizumi,Kiyoshi; Shimizu,Kazuo; Zhou,Hai‑Meng; Jablons,David; He,Biao

doi:10.3892/or.2015.3771

Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma

Authors:
- Tomomi Hirata
- Qingfeng Zheng
- Zhao Chen
- Hiroyasu Kinoshita
- Junichi Okamoto
- Johannes Kratz
- Hui Li
- Natalie Lui
- Hanh Do
- Tiffany Cheng
- Hsin-Hui Katty Tseng
- Kiyoshi Koizumi
- Kazuo Shimizu
- Hai‑Meng Zhou
- David Jablons
- Biao He
View Affiliations

Affiliations: Thoracic Oncology Program, Department of Surgery, University of California, San Francisco, CA 94115, USA, Department of Surgery, Division of Thoracic Surgery, Nippon Medical School, Tokyo 113‑8602, Japan, School of Life Sciences, Tsinghua University, Beijing 100084, P.R. China
Published online on: January 29, 2015 https://doi.org/10.3892/or.2015.3771
Pages: 2052-2060

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that has a poor prognosis, limited treatment options, and a worldwide incidence that is expected to increase in the next decade. We evaluated Wnt7A expression in 50 surgically resected tumor specimens using quantitative PCR. The expression values, were assessed by clinicopathological factors and K-M and Cox's regression with OS. The mean level of Wnt7A expression had a significant correlation with International Mesothelioma Interest Group (IMIG) stage (P<0.034), gender, smoking history and ethnicity, respectively (P=0.020, P=0.014, P=0.039). In the univariate analysis, low Wnt7A expression was a significant negative factor for overall survival (P=0.043, HR=2.30). However, multivariate Cox's regression revealed no significant factors for overall survival (low Wnt7A: P=0.051, HR=2.283; non-epithelioid subtype: P=0.050, HR=2.898). In patients with epithelioid tumors, those with low Wnt7A expression had significantly worse prognosis (P=0.019, HR=2.98). In patients with epithelioid tumors, females had significantly better prognosis than males (P=0.035). In patients who did not have neoadjuvant chemotherapy, prognosis was significantly more favorable for patients with high Wnt7A expression than for those with low Wnt7A expression (P=0.031). Among the patients with low Wnt7A-expressing tumors, those who received neoadjuvant chemotherapy had better prognosis than those who did not (P=0.024). The results of our study suggest that Wnt7A expression is a putative prognostic factor and a predictor of chemosensitivity.

View Figures

View References

1	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
2	Musk AW and de Klerk NH: Epidemiology of malignant mesothelioma in Australia. Lung Cancer. 45:S21–S23. 2004. View Article : Google Scholar : PubMed/NCBI
3	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
4	Borasio P, Berruti A, Bille A, et al: Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 33:307–313. 2008. View Article : Google Scholar : PubMed/NCBI
5	Flores RM, Zakowski M, Venkatraman E, et al: Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
6	Krug LM, Pass HI, Rusch VW, et al: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
7	Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y and Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 113:723–731. 1998. View Article : Google Scholar : PubMed/NCBI
8	Neumann V, Rutten A, Scharmach M, Muller KM and Fischer M: Factors influencing long-term survival in mesothelioma patients-results of the German mesothelioma register. Int Arch Occup Environ Health. 77:191–199. 2004. View Article : Google Scholar : PubMed/NCBI
9	Metintas M, Metintas S, Ucgun I, et al: Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med. 95:829–835. 2001. View Article : Google Scholar : PubMed/NCBI
10	Baas P: Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol. 15:127–130. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kumar-Singh S, Jacobs W, Dhaene K, et al: Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol. 186:300–305. 1998. View Article : Google Scholar
12	Edwards JG, Swinson DE, Jones JL, Waller DA and O’Byrne KJ: EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 54:399–407. 2006. View Article : Google Scholar : PubMed/NCBI
13	Edwards JG, Faux SP, Plummer SM, et al: Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res. 8:1857–1862. 2002.PubMed/NCBI
14	Lopez-Rios F, Chuai S, Flores R, et al: Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 66:2970–2979. 2006. View Article : Google Scholar : PubMed/NCBI
15	Gordon GJ, Rockwell GN, Godfrey PA, et al: Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 11:4406–4414. 2005. View Article : Google Scholar : PubMed/NCBI
16	Shimizu E, Coxon A, Otterson GA, et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 9:2441–2448. 1994.PubMed/NCBI
17	Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A and Kaye FJ: Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene. 19:4632–4639. 2000. View Article : Google Scholar : PubMed/NCBI
18	Giacinti C and Giordano A: RB and cell cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
19	Cote RJ, Jhanwar SC, Novick S and Pellicer A: Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 51:5410–5416. 1991.PubMed/NCBI
20	Wong L, Zhou J, Anderson D and Kratzke RA: Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer. 38:131–136. 2002. View Article : Google Scholar : PubMed/NCBI
21	Yang CT, You L, Yeh CC, et al: Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst. 92:636–641. 2000. View Article : Google Scholar : PubMed/NCBI
22	Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
23	Boersma CJ, Bloemen M, Hendriks JM, van Berkel EA, Olijve W and van Zoelen EJ: Homeobox proteins as signal transduction intermediates in regulation of NCAM expression by recombinant human bone morphogenetic protein-2 in osteoblast-like cells. Mol Cell Biol Res Commun. 1:117–124. 1999. View Article : Google Scholar : PubMed/NCBI
24	Ohira T, Gemmill RM, Ferguson K, et al: WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA. 100:10429–10434. 2003. View Article : Google Scholar : PubMed/NCBI
25	Riddle RD, Ensini M, Nelson C, Tsuchida T, Jessell TM and Tabin C: Induction of the LIM homeobox gene Lmx1 by WNT7a establishes dorsoventral pattern in the vertebrate limb. Cell. 83:631–640. 1995. View Article : Google Scholar : PubMed/NCBI
26	Timmreck LS, Pan HA, Reindollar RH and Gray MR: WNT7A mutations in patients with Mullerian duct abnormalities. J Pediatr Adolesc Gynecol. 16:217–221. 2003. View Article : Google Scholar : PubMed/NCBI
27	Bui TD, Lako M, Lejeune S, et al: Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25. Gene. 189:25–29. 1997. View Article : Google Scholar : PubMed/NCBI
28	Kirikoshi H and Katoh M: Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol. 21:895–900. 2002.PubMed/NCBI
29	Raz DJ, Ray MR, Kim JY, et al: A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 14:5565–5570. 2008. View Article : Google Scholar : PubMed/NCBI
30	Fennell DA, Parmar A, Shamash J, et al: Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 23:184–189. 2005. View Article : Google Scholar
31	Miller C, Degenhardt K and Sassoon DA: Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet. 20:228–230. 1998. View Article : Google Scholar : PubMed/NCBI
32	Mericskay M, Kitajewski J and Sassoon D: Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development. 131:2061–2072. 2004. View Article : Google Scholar : PubMed/NCBI
33	Parr BA and McMahon AP: Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature. 395:707–710. 1998. View Article : Google Scholar : PubMed/NCBI
34	Li S, Chiang TC, Davis GR, Williams RM, Wilson VP and McLachlan JA: Decreased expression of Wnt7a mRNA is inversely associated with the expression of estrogen receptor-alpha in human uterine leiomyoma. J Clin Endocrinol Metab. 86:454–457. 2001.PubMed/NCBI
35	Pinton G, Brunelli E, Murer B, et al: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 69:4598–4604. 2009. View Article : Google Scholar : PubMed/NCBI
36	Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2:777–785. 2002. View Article : Google Scholar : PubMed/NCBI
37	Andujar P, Wang J, Descatha A, et al: p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer. 67:23–30. 2010. View Article : Google Scholar
38	Becklake MR, Thomas D, Liddell F and McDonald JC: Follow-up respiratory measurements in Quebec chrysotile asbestos miners and millers. Scand J Work Environ Health. 8:105–110. 1982.PubMed/NCBI
39	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
40	Flores EM: Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer. 49:S71–S74. 2005. View Article : Google Scholar : PubMed/NCBI
41	Tsao AS, Mehran R and Roth JA: Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 10:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
42	Weder W, Kestenholz P, Taverna C, et al: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 22:3451–3457. 2004. View Article : Google Scholar : PubMed/NCBI